CBT Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:CBT Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11103
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
CBT Pharmaceuticals Inc (CBT) is a pharmaceutical company that develops innovative medicines for cancer indications. The company’s pipeline products include CBT-101, cMet inhibitor is being developed to target the epithelial to mesenchymal transition pathway. Its CBT-101 is developed for various cancer indications, including kidney, esophageal, lung, gastric, colorectal and brain cancer. The company’s other products in preclinical phase include, CBT-102, multi-targeted kinase inhibitor is being developed for liver, breast, colorectal and non-small cell lung cancer diseases. It operates in Taiwan and the US. CBT is headquartered in Pleasanton, California, the US.

CBT Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
CBT Pharma Raises USD9.8 Million in Series A Financing 10
CBT Pharma Raises USD5 Million in Seed Financing 11
Partnerships 12
CBT Pharma Enters into Agreement with CrystalGenomics 12
Licensing Agreements 13
CBT Pharma Enters into Licensing Agreement with Crown Bioscience 13
CBT Pharma Enters into Licensing Agreement with Crown Bioscience 14
CBT Pharmaceuticals Inc – Key Competitors 15
CBT Pharmaceuticals Inc – Key Employees 16
CBT Pharmaceuticals Inc – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Corporate Communications 18
Aug 16, 2018: CBT Pharmaceuticals announces new leadership structure to drive global expansion 18
Aug 28, 2017: CBT Pharmaceuticals Appoints Nationally Recognized Leaders in Oncology to Newly Established Scientific Advisory Board 19
Government and Public Interest 20
Oct 15, 2018: CBT Pharmaceuticals awarded NIH small business innovation research grant towards development of combination checkpoint inhibition 20
Clinical Trials 21
Apr 17, 2018: BT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of Its Multi-Tyrosine Kinase Inhibitor, CBT-102, at AACR Annual Meeting 2018 21
Oct 30, 2017: CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its PD-L1 Immunotherapy Antibody, CBT-502 at the AACR-NCI-EORTC International Conference on Molecular Target and Cancer Therapeutics 22
Sep 28, 2017: CBT Pharmaceuticals Announces First U.S. Patient Dosed in Phase 1 Clinical Trial of c-Met inhibitor, CBT-101, for Advanced Solid Tumors with c-Met Dysregulation 23
Apr 04, 2017: CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its Highly Specific c-MET Inhibitor, Bozitinib (CBT-101), at AACR Annual Meeting 2017 24
Mar 30, 2017: First-in-Human Genolimzumab Phase 1 Study Initiated to Assess Safety and Preliminary Efficacy in Patients with Select Advanced Solid Tumors 25
Feb 23, 2017: CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its Programmed Death-1 antibody, CBT-501, at ASCO-SITC Clinical Oncology Symposium 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
CBT Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
CBT Pharma Raises USD9.8 Million in Series A Financing 10
CBT Pharma Raises USD5 Million in Seed Financing 11
CBT Pharma Enters into Agreement with CrystalGenomics 12
CBT Pharma Enters into Licensing Agreement with Crown Bioscience 13
CBT Pharma Enters into Licensing Agreement with Crown Bioscience 14
CBT Pharmaceuticals Inc, Key Competitors 15
CBT Pharmaceuticals Inc, Key Employees 16

List of Figures
CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
CBT Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[CBT Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Hetero Drugs Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Hetero Drugs Ltd (Hetero) is a manufacturer of active pharmaceutical ingredients, intermediate chemicals and finished dosages. The company specializes in process chemistry, API manufacturing, formulation development, manufacturing and commercialization of bio-generics, and also offers custom …
  • Avis Budget Group, Inc.:戦略・SWOT・企業財務分析
    Avis Budget Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Avis Budget Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • KFG Resources Ltd (KFG):企業の財務・戦略的SWOT分析
    Summary KFG Resources Ltd (KFG) is a petroleum and natural gas exploration company that supplies natural gas. The company produces crude oil and natural gas through its reserves. Its oil and gas reserves are located in Mississippi, Wilcox, and Louisiana. KFG’s Mississippi’s projects comprise Carthag …
  • Greensmith Energy Management Systems LLC-エネルギー分野:企業M&A・提携分析
    Summary Greensmith Energy Management Systems, LLC (Greensmith) is a provider of energy storage management and services. The company specializes in software and control solutions to operate and manage Distributed Energy Storage Systems (DESS) for utility-scale, C&I or Micro-grid deployments. It offer …
  • Sumi-Eagle Corp:企業の戦略的SWOT分析
    Sumi-Eagle Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Fuller, Smith & Turner Plc:企業の戦略・SWOT・財務分析
    Fuller, Smith & Turner Plc - Strategy, SWOT and Corporate Finance Report Summary Fuller, Smith & Turner Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Sulzer Ltd (SUN):企業の財務・戦略的SWOT分析
    Sulzer Ltd (SUN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Cellect Biotechnology Ltd (APOP):製薬・医療:M&Aディール及び事業提携情報
    Summary Cellect Biotechnology Ltd (Cellect Biotechnology) formerly Cellect Biomed Ltd is a clinical stage biotechnology company which develops stem cell selection technologies for the production of stem cells based products in the field of regenerative medicine. The company’s technology platform is …
  • Intech Biopharm Ltd (6461):医療機器:M&Aディール及び事業提携情報
    Summary Intech Biopharm Ltd (Intech Biopharm) is a drug developing company that develops drugs for obstructive airway diseases. The company provides marketed products such as single ingredient generics such as Synvent, and Duasma, developed for asthma; and multi-ingredient generic, Synflutide, for a …
  • Jelf Group PLC:企業のM&A・事業提携・投資動向
    Jelf Group PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Jelf Group PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Underwriters Laboratories Inc.:企業のM&A・事業提携・投資動向
    Underwriters Laboratories Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Underwriters Laboratories Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Urigen Pharmaceuticals Inc:企業の戦略的SWOT分析
    Urigen Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Mizuho Trust & Banking Co Ltd:企業の戦略・SWOT・財務分析
    Mizuho Trust & Banking Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Mizuho Trust & Banking Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • RegeneRx Biopharmaceuticals Inc (RGRX):企業の財務・戦略的SWOT分析
    Summary RegeneRx Biopharmaceuticals Inc (RegeneRx) is a clinical-stage biopharmaceutical company that designs, researches and develops novel peptides targeted at diseases with unmet medical needs. The company offers clinical trials, science and discovery and business development services. Its busine …
  • AvidBiotics Corp-製薬・医療分野:企業M&A・提携分析
    Summary AvidBiotics Corp (AvidBiotics) is a healthcare company that develops non-antibody proteins targeting cancer, bacteria and virus-infected cells. The company develops a portfolio of therapeutic protein candidates and protein engineering platforms which include avidocin proteins, mica-body prot …
  • EndoGastric Solutions Inc-製薬・医療分野:企業M&A・提携分析
    Summary EndoGastric Solutions Inc (EGS), formerly EsophyX, Inc. is a medical equipment company that manufactures and markets gastroenterology and surgical products. The company’s products include esophy-x device and serosa-fuse fasteners. Its esophy-x device is used in reconstructing the gastroesoph …
  • OJSC Surgutneftegas:企業の戦略・SWOT・財務分析
    OJSC Surgutneftegas - Strategy, SWOT and Corporate Finance Report Summary OJSC Surgutneftegas - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Circassia Pharmaceuticals Plc (CIR):医療機器:M&Aディール及び事業提携情報
    Summary Circassia Pharmaceuticals plc (Circassia) develops and manufactures drugs for the treatment of allergy and respiratory diseases such as asthma. The company’s marketed products include Niox used to assist asthma management and Tudorza for the treatment of chronic obstructive pulmonary disease …
  • Medical Facilities Corp (DR):製薬・医療:M&Aディール及び事業提携情報
    Summary Medical Facilities Corp (MFC) is a healthcare service provider that provides inpatient and outpatient surgical procedures. The hospital offers surgical equipment, non-surgical professional services, drugs and supplies, and other support services. Its specialty surgical division performs non- …
  • Ascent Solar Technologies Inc (ASTI)-エネルギー分野:企業M&A・提携分析
    Summary Ascent Solar Technologies, Inc. (Ascent solar) is a developer and manufacturer of thin-film photovoltaic modules using substrate materials. It develops products by using thin-film copper-indium-gallium- diselenide (CIGS) photovoltaic technology. The product portfolio of the company includes …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆